Cargando…

Population pharmacokinetics of FCN-159, a MEK1/2 inhibitor, in adult patients with advanced melanoma and neurofibromatosis type 1 (NF1) and model informed dosing recommendations for NF1 pediatrics

Objective: FCN-159 is a highly active mitogen-activated extracellular signal-regulated kinase 1/2 (MEK1/2) inhibitor in patients with advanced melanoma and neurofibromatosis type 1 (NF1). We report a population pharmacokinetic (PopPK) model-based analysis of FCN-159 and its application to inform dos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Yan, Cui, Ailing, Qian, Lixuan, Li, Chao, Wu, Zhuli, Yang, Yuchen, Han, Pu, Huang, Xin, Diao, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899833/ https://www.ncbi.nlm.nih.gov/pubmed/36755948 http://dx.doi.org/10.3389/fphar.2023.1101991

Ejemplares similares

Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas
por: Hu, Xiaojie, et al.
Publicado: (2023)

Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma
por: Gutmann, David H., et al.
Publicado: (2013)

A novel neurofibromatosis type 1 (NF1) mutation in a patient with NF1 and pheochromocytoma
por: Seo, Yoorim, et al.
Publicado: (2018)

Effect of Polymorphisms in the FCN1, FCN2, and FCN3 Genes on the Susceptibility to Develop Rheumatoid Arthritis: A Systematic Review
por: Gil-Quiñones, Sebastián R., et al.
Publicado: (2022)

Complications of Neurofibromatosis 1 (NF1) in an Adult With Multiple Comorbidities
por: Nnomadim, Ozioma P, et al.
Publicado: (2021)

The Spectrum of NF1 Mutations in Korean Patients with Neurofibromatosis Type 1
por: Jeong, Seon-Yong, et al.
Publicado: (2006)

Cohort profile: life with neurofibromatosis 1 – the Danish NF1 cohort
por: Doser, Karoline, et al.
Publicado: (2022)

The Perceived Influence of Neurofibromatosis Type 1(NF1) on the Parents’ Relationship
por: Wiener, Lori, et al.
Publicado: (2023)

Phase 1a study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR + /HER2- advanced breast cancer
por: Zhang, Jian, et al.
Publicado: (2021)

Somatic deletion of the NF1 gene in a neurofibromatosis type 1-associated malignant melanoma demonstrated by digital PCR
por: Rübben, Albert, et al.
Publicado: (2006)

Risk Factors for Bullying Victimization in Children with Neurofibromatosis Type 1 (NF1)
por: Stavinoha, Peter L., et al.
Publicado: (2021)

Impacts of NF1 Gene Mutations and Genetic Modifiers in Neurofibromatosis Type 1
por: Wang, Wei, et al.
Publicado: (2021)

NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas
por: Weiss, Brian D., et al.
Publicado: (2021)

Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1
por: Walsh, Karin S., et al.
Publicado: (2021)

Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire
por: Ferner, Rosalie E, et al.
Publicado: (2017)

Autism Spectrum Disorder in an Unselected Cohort of Children with Neurofibromatosis Type 1 (NF1)
por: Eijk, S., et al.
Publicado: (2018)

Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq
por: Koster, R., et al.
Publicado: (2021)

Management of spinal deformities and tibial pseudarthrosis in children with neurofibromatosis type 1 (NF-1)
por: Mladenov, Kiril V., et al.
Publicado: (2020)

NFB-17. "Optic Pathway findings in children with Neurofibromatosis type-1 (NF-1)
por: Roka, Kleoniki, et al.
Publicado: (2022)

Neurofibromatosis Type 1 (NF1): Addressing the Transition from Pediatric to Adult Care
por: Radtke, Heather B, et al.
Publicado: (2023)

Genotype-phenotype associations in neurofibromatosis type 1 (NF1): an increased risk of tumor complications in patients with NF1 splice-site mutations?
por: Alkindy, Adila, et al.
Publicado: (2012)

NF1 mutations in conjunctival melanoma
por: Scholz, S. L., et al.
Publicado: (2018)

Protein phosphatase 6 regulates trametinib sensitivity, a mitogen-activated protein kinase kinase (MEK) inhibitor, by regulating MEK1/2-ERK1/2 signaling in canine melanoma cells
por: YAMAMOTO, Miu, et al.
Publicado: (2023)

Spinal neurofibromatosis with NF1 mutation in a classic neurofibromatosis type 1 family: A case report and literature review
por: Ning, Zeqian, et al.
Publicado: (2019)

Accurate Classification of NF1 Gene Variants in 84 Italian Patients with Neurofibromatosis Type 1
por: Stella, Alessandro, et al.
Publicado: (2018)

Can the Cognitive Phenotype in Neurofibromatosis Type 1 (NF1) Be Explained by Neuroimaging? A Review
por: Baudou, Eloïse, et al.
Publicado: (2020)

Correction to: Management of spinal deformities and tibial pseudarthrosis in children with neurofibromatosis type 1 (NF-1)
por: Mladenov, Kiril V., et al.
Publicado: (2021)

Exploring associations between constipation, severity of neurofibromatosis type 1 and NF1 mutational spectrum
por: Ejerskov, Cecilie, et al.
Publicado: (2021)

Mutational spectrum of NF1 gene in 24 unrelated Egyptian families with neurofibromatosis type 1
por: N. Abdel‐Aziz, Nahla, et al.
Publicado: (2021)

Are neurofibromatosis type 1 (NF1) patients at increased risk of meningioma and in particular malignant meningioma?
por: Evans, D. Gareth R., et al.
Publicado: (2022)

Mathematical Modeling and Nail Placement Accuracy Analysis of NF-1 Neurofibromatosis Scoliosis
por: Yan, Guangxuan, et al.
Publicado: (2022)

Deep Intronic LINE-1 Insertions in NF1: Expanding the Spectrum of Neurofibromatosis Type 1-Associated Rearrangements
por: Alesi, Viola, et al.
Publicado: (2023)

Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanoma
por: Zhao, Qian, et al.
Publicado: (2022)

Neurofibromatosis Type 1: A Novel NF1 Mutation Associated with Mitochondrial Complex I Deficiency
por: Domingues, Sara, et al.
Publicado: (2014)

Molecular Characterization of NF1 and Neurofibromatosis Type 1 Genotype-Phenotype Correlations in a Chinese Population
por: Zhang, Jia, et al.
Publicado: (2015)

Clinical characteristics and spectrum of NF1 mutations in 12 unrelated Chinese families with neurofibromatosis type 1
por: Mao, Bin, et al.
Publicado: (2018)

Acute Deterioration of Pulmonary Arterial Hypertension (PAH) in a Patient with Neurofibromatosis Type 1 (NF1)
por: Tanaka, Seiya, et al.
Publicado: (2019)

The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation
por: Solga, Anne C, et al.
Publicado: (2017)

Isoform-specific NF1 mRNA levels correlate with disease severity in Neurofibromatosis type 1
por: Assunto, Antonia, et al.
Publicado: (2019)

Identification of a Novel NF1 Frameshift Variant in a Chinese Family with Neurofibromatosis Type 1
por: Xu, Guoyao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qaqkhj28tshpnb2b57hdeeqjp0